Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH (2013) JAMA 309: 578-86 The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Behr ER, January C, Schulze-Bahr E, Grace AA, Kääb S, Fiszman M, Gathers S, Buckman S, Youssef A, Pirmohamed M, Roden D (2013) Eur Heart J 34: 1958-63 Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics. Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I (1980) Ann Intern Med 93: 62-89 High-field NMR studies of molecular recognition and structure-function relationships in antimicrobial piscidins at the water-lipid bilayer interface. Chekmenev EY, Jones SM, Nikolayeva YN, Vollmar BS, Wagner TJ, Gor'kov PL, Brey WW, Manion MN, Daugherty KC, Cotten M (2006) J Am Chem Soc 128: 5308-9 Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR (2003) Clin Infect Dis 37: 187-95 Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM (1987) Kidney Int 32: 884-8 Specific deletion of glycogen synthase kinase-3β in the renal proximal tubule protects against acute nephrotoxic injury in mice. Howard C, Tao S, Yang HC, Fogo AB, Woodgett JR, Harris RC, Rao R (2012) Kidney Int 82: 1000-9 Subversion of antimicrobial calprotectin (S100A8/S100A9 complex) in the cytoplasm of TR146 epithelial cells after invasion by Listeria monocytogenes. Zaia AA, Sappington KJ, Nisapakultorn K, Chazin WJ, Dietrich EA, Ross KF, Herzberg MC (2009) Mucosal Immunol 2: 43-53 Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Bernard GR (2003) Crit Care Med 31: S85-93 Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR, PROWESS Investigators (2003) Crit Care Med 31: 12-9 A 14-year-old boy with kidney allograft failure in the first month after transplantation. Revelo MP, Paueksakon P, Goral S, Helderman H, Fogo AB (2000) Am J Kidney Dis 36: 871-4 Dapsone-induced methemoglobinemia: a dose-related occurrence? Esbenshade AJ, Ho RH, Shintani A, Zhao Z, Smith LA, Friedman DL (2011) Cancer 117: 3485-92 Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections. Williams DJ, Cooper WO, Kaltenbach LA, Dudley JA, Kirschke DL, Jones TF, Arbogast PG, Griffin MR, Creech CB (2011) Pediatrics 128: e479-87 A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW (2001) Inflamm Bowel Dis 7: 301-5 Glucan phosphate potentiates endotoxin-induced interferon-gamma expression in immunocompetent mice, but attenuates induction of endotoxin tolerance. Sherwood ER, Varma TK, Fram RY, Lin CY, Koutrouvelis AP, Toliver-Kinsky TE (2001) Clin Sci (Lond) 101: 541-50 Use of vaginally administered chlorhexidine during labor to improve pregnancy outcomes. Goldenberg RL, McClure EM, Saleem S, Rouse D, Vermund S (2006) Obstet Gynecol 107: 1139-46 Vaginal preparation with povidone iodine and postcesarean infectious morbidity: a randomized controlled trial. Reid VC, Hartmann KE, MCMahon M, Fry EP (2001) Obstet Gynecol 97: 147-52 Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C (1996) Am J Med 101: 68-76 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. Corbett AH, Hong D, Osheroff N (1993) J Biol Chem 268: 14394-8 A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. Elsea SH, Hsiung Y, Nitiss JL, Osheroff N (1995) J Biol Chem 270: 1913-20 Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) J Biol Chem 274: 35927-32 A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. Hsiung Y, Elsea SH, Osheroff N, Nitiss JL (1995) J Biol Chem 270: 20359-64 Topoisomerase IV catalysis and the mechanism of quinolone action. Anderson VE, Gootz TD, Osheroff N (1998) J Biol Chem 273: 17879-85 Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N (1991) J Biol Chem 266: 14585-92 Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. Elsea SH, Osheroff N, Nitiss JL (1992) J Biol Chem 267: 13150-3 Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N (1992) Antimicrob Agents Chemother 36: 751-6 A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential. Corbett AH, Guerry P, Pflieger P, Osheroff N (1993) Antimicrob Agents Chemother 37: 2599-605 Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N (1993) Antimicrob Agents Chemother 37: 2179-86 Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. Vaezi MF, Slaughter JC, Smith BS, Washington MK, Jerome WG, Garrett CG, Hagaman D, Goutte M (2010) Aliment Pharmacol Ther 32: 916-24 Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets. Rotsinger JE, Celada LJ, Polosukhin VV, Atkinson JB, Drake WP (2016) Am J Respir Cell Mol Biol 55: 128-34 OxyR Regulates the Transcriptional Response to Hydrogen Peroxide. Juttukonda LJ, Green ER, Lonergan ZR, Heffern MC, Chang CJ, Skaar EP (2019) Infect Immun 87: Frequency of disinfectant resistance genes in pediatric strains of methicillin-resistant Staphylococcus aureus. Johnson JG, Saye EJ, Jimenez-Truque N, Soper N, Thomsen I, Talbot TR, Creech CB (2013) Infect Control Hosp Epidemiol 34: 1326-7 Pharmacogenomics of antimicrobial agents. Aung AK, Haas DW, Hulgan T, Phillips EJ (2014) Pharmacogenomics 15: 1903-30 IL-17a and IL-22 Induce Expression of Antimicrobials in Gastrointestinal Epithelial Cells and May Contribute to Epithelial Cell Defense against Helicobacter pylori. Dixon BR, Radin JN, Piazuelo MB, Contreras DC, Algood HM (2016) PLoS One 11: e0148514 Role of sphingomyelin synthase in controlling the antimicrobial activity of neutrophils against Cryptococcus neoformans. Qureshi A, Subathra M, Grey A, Schey K, Del Poeta M, Luberto C (2010) PLoS One 5: e15587 Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy. Veach RA, Zienkiewicz J, Collins RD, Hawiger J (2012) PLoS One 7: e30527 Evaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses. Holden WM, Ebert AR, Canning PF, Rollins-Smith LA (2014) Appl Environ Microbiol 80: 4034-41 Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Robinson MJ, Corbett AH, Osheroff N (1993) Biochemistry 32: 3638-43 Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Bromberg KD, Burgin AB, Osheroff N (2003) Biochemistry 42: 3393-8 Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (2000) Biochemistry 39: 2726-32
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.